Literature DB >> 31630447

SERPINB2 and miR-146a/b are coordinately regulated and act in the suppression of psoriasis-associated inflammatory responses in keratinocytes.

Helen Vaher1, Anet Kivihall1, Toomas Runnel1, Liisi Raam2,3, Ele Prans1, Julia Maslovskaja1, Kristi Abram3, Bret Kaldvee2,3, Ulrich Mrowietz4, Stephan Weidinger5, Külli Kingo2,3, Ana Rebane1.   

Abstract

Psoriasis is a chronic inflammatory skin disease with numerous involved factors. miR-146a and miR-146b (miR-146a/b) are anti-inflammatory miRNAs that are increased in psoriatic skin. SERPINB2 has been shown to be upregulated in the inflammation and infections. Here we aimed to study the relationship between miR-146a/b and SERPINB2 and to delineate the role of SERPINB2 in association of plaque psoriasis. We report increased SERPINB2 expression in the skin of psoriasis patients, which was in a positive relationship with psoriasis severity and in a negative relationship with miR-146a/b in psoriatic lesions. In cultured keratinocytes, both cellular and secreted SERPINB2 levels were strongly induced in response to IFN-γ and TNF-α. Interestingly, SERPINB2 mRNA was downregulated by IL-17A and the combination of TNF-α and IL-17A at time points when miR-146a was increased. The predicted binding site for miR-146a/b in 3' untranslated region of SERPINB2 revealed no activity in luciferase assay, while siRNA silencing of miR-146a/b direct targets IRAK1 and CARD10 resulted in reduced expression of SERPINB2, suggesting that miR-146a/b indirectly control SERPINB2 expression in the skin. The siRNA silencing of SERPINB2 increased the expression of IL-8, CXCL5 and CCL5 and migration of neutrophils revealing its anti-inflammatory role in keratinocytes. Our data together suggest that SERPINB2 and miR-146a/b are part of disease-related network of molecules that are coordinately regulated and act in controlling the inflammatory responses in psoriatic skin.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  inflammation; microRNA; protease inhibitor; skin

Mesh:

Substances:

Year:  2019        PMID: 31630447     DOI: 10.1111/exd.14049

Source DB:  PubMed          Journal:  Exp Dermatol        ISSN: 0906-6705            Impact factor:   3.960


  7 in total

Review 1.  SERPINB2-its regulation and interplay with aryl hydrocarbon receptor.

Authors:  Damian Brauze
Journal:  J Appl Genet       Date:  2021-01-02       Impact factor: 3.240

2.  Estrogen Acts Through Estrogen Receptor-β to Promote Mannan-Induced Psoriasis-Like Skin Inflammation.

Authors:  Huimei Wu; Longhui Zeng; Jiaxin Ou; Tingting Wang; Yong Chen; Kutty Selva Nandakumar
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

3.  EZH2 is involved in psoriasis progression by impairing miR-125a-5p inhibition of SFMBT1 and leading to inhibition of the TGFβ/SMAD pathway.

Authors:  Shengming Qu; Zhe Liu; Bing Wang
Journal:  Ther Adv Chronic Dis       Date:  2021-04-15       Impact factor: 5.091

Review 4.  Anti-Inflammatory microRNAs for Treating Inflammatory Skin Diseases.

Authors:  Shih-Chun Yang; Ahmed Alalaiwe; Zih-Chan Lin; Yu-Chih Lin; Ibrahim A Aljuffali; Jia-You Fang
Journal:  Biomolecules       Date:  2022-08-03

5.  HMSC-Derived Exosome Inhibited Th2 Cell Differentiation via Regulating miR-146a-5p/SERPINB2 Pathway.

Authors:  Jing Zhou; Yi Lu; Wei Wu; Yunhai Feng
Journal:  J Immunol Res       Date:  2021-05-14       Impact factor: 4.818

6.  Dual role of the miR-146 family in rhinovirus-induced airway inflammation and allergic asthma exacerbation.

Authors:  Anet Laanesoo; Egon Urgard; Kapilraj Periyasamy; Martti Laan; Yury A Bochkov; Alar Aab; Nathaniel Magilnick; Margus Pooga; James E Gern; Sebastian L Johnston; Jonathan M Coquet; Mark P Boldin; Jesper Wengel; Alan Altraja; Grazyna Bochenek; Bogdan Jakiela; Ana Rebane
Journal:  Clin Transl Med       Date:  2021-06

7.  MicroRNA-146a and microRNA-146b deficiency correlates with exacerbated disease activity, and their longitude increment relates to etanercept response in psoriasis patients.

Authors:  Hui Shen; Dan Wang; Mengyun Zhan; Hanping Ding; Hongbo Zhao
Journal:  J Clin Lab Anal       Date:  2021-12-24       Impact factor: 2.352

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.